Promises
1 promise
Promise Tracker
0 delivered, 0 close, 1 missed.
View Promises →Gland Pharma Limited — Q1 FY26
Gland Pharma reported a solid Q1 FY26 with consolidated revenue of INR 1,506 crore (+7% YoY) and EBITDA of INR 368 crore (+39% YoY), driving margins to 24% (up 500bps YoY).
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Gland Pharma reported a solid Q1 FY26 with consolidated revenue of INR 1,506 crore (+7% YoY) and EBITDA of INR 368 crore (+39% YoY), driving margins to 24% (up 500bps YoY). PAT surged 50% YoY to INR 216 crore. The standout was Cenexi reaching EBITDA break-even (EUR 0.9 million) after several quarters of losses, aided by volume recovery and cost actions. Base business EBITDA margin improved to 35% (vs 29% YoY). U.S. revenue was flat due to Enoxaparin timing, but ex that grew 11%. Management reiterated mid-teen overall growth guidance, backed by upcoming launches of dalbavancin and CMS dry powder. GLP-1 cartridge capacity expansion to 140 million units by March 2026 is on track, with 20 million units expected to commercialize in FY27. Key risk: Cenexi's Q2 may dip due to summer shutdown, delaying margin ramp-up.
ग्लैंड फार्मा ने पहली तिमाही में अच्छा प्रदर्शन किया। कुल कमाई 1,506 करोड़ रुपये रही, जो पिछले साल से 7% ज्यादा है। कंपनी का मुनाफा 216 करोड़ रुपये रहा, जो 50% बढ़ा। खास बात यह रही कि यूरोप की कंपनी सेनेक्सी ने घाटा खत्म कर बराबरी हासिल की। अमेरिका में बिक्री स्थिर रही, लेकिन एक दवा को छोड़कर 11% बढ़ी। कंपनी को उम्मीद है कि पूरे साल कमाई 15% तक बढ़ेगी। नई दवाएं लॉन्च होंगी और इंजेक्शन कार्ट्रिज बनाने की क्षमता बढ़ रही है। जोखिम: सेनेक्सी की अगली तिमाही गर्मी की छुट्टी के कारण कमजोर रह सकती है।
Promises0 met · 1 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Risks
4 risks
Risk Intelligence
Cenexi Q2 dip due to summer shutdown
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Cenexi EBITDA
EUR 0.9M
from negative to positive
Cenexi reached EBITDA break-even for the first time, a significant turnaround from prior losses.
Base Business EBITDA Margin
35%
+600bps YoY
Excluding Cenexi, base business EBITDA margin expanded sharply from 29% to 35%.
Gross Margin (Consolidated)
65%
+500bps YoY
Consolidated gross margin improved to 65% from 60% YoY, driven by favorable raw material costs.
GLP-1 Cartridge Capacity
140M units
+100M units by Mar'26
Total cartridge fill-finish capacity to reach 140 million units by March 2026, up from 40 million currently.
What Changed vs Last Quarter
NEW
20 million GLP-1 units commercialization in FY27
Management expects to commercialize around 20 million pens/cartridges in FY27, primarily for RoW markets.
UPDATED
Cenexi positive EBITDA by Q3 FY26
Management expects Cenexi to deliver positive EBITDA in Q3 FY26, with Q2 being lower due to summer shutdown.
UPDATED
Mid-teen overall revenue growth for FY26
Management reiterated guidance for mid-teen consolidated revenue growth for the full year, driven by U.S. launches and Cenexi recovery.
UPDATED
GLP-1 cartridge capacity expansion to 140M by Mar'26
The new 100 million cartridge line will be ready for commercialization by March 2026, adding to the existing 40 million capacity.
DROPPED
Biologics revenue of INR 100 crore in FY26
The biologics segment, including the Dr. Reddy's collaboration, is expected to contribute approximately INR 100 crore in revenue in FY26.
NEW RISK
Cenexi Q2 dip due to summer shutdown
Management acknowledged that Q2 FY26 will see lower EBITDA at Cenexi due to a one-month thermal shutdown, potentially delaying the turnaround trajectory.
NEW RISK
U.S. tariff uncertainty on pharmaceuticals
An analyst raised concerns about potential U.S. tariffs under the Trump administration. Management noted no tariffs on pharma yet but acknowledged uncertainty and said they would pass on costs to partners.
NEW RISK
Enoxaparin revenue volatility
U.S. revenue was flat due to timing of Enoxaparin supplies, a large product. Management expects annual volumes to be intact but quarterly volatility may persist.
NEW RISK
GLP-1 capacity utilization ramp-up slower than expected
Management indicated that the new 100 million cartridge line will not see significant utilization until FY29-30, as most markets open later. Near-term revenue contribution may be limited.
RISK GONE
Cenexi turnaround execution risk
Cenexi's performance has been below expectations, with losses persisting due to remediation activities and equipment breakdowns. Achieving positive EBITDA by Q3 FY26 is uncertain.
RISK GONE
U.S. tariff impact on generics
The U.S. administration's reciprocal tariffs create uncertainty for Indian pharma companies. While management expects minimal impact on generics, the situation remains fluid.
RISK GONE
ROW market tender losses
The ROW segment saw a 14% revenue decline in Q4 due to tender misses and softer offtake. Recovery depends on re-engaging local partners and executing a non-Enoxa strategy.
RISK GONE
Cenexi capital allocation concerns
Analysts questioned the return on invested capital for Cenexi, given the high acquisition cost and additional capex. Management's target of 18% EBITDA on $300M revenue may still yield suboptimal ROCE.
🤫 Topics management stopped discussing
Mentioned in Q1 FY25, Q2 FY25, Q4 FY25
Cenexi's performance has been below expectations, with losses persisting due to remediation activities and equipment breakdowns. Achieving positive EBITDA by Q3 FY26 is uncertain.
Mentioned in Q1 FY25, Q4 FY25
Management expects consolidated revenue to grow in the mid-teens percentage range in FY26, driven by new launches, CMO projects, and biologics.
Mentioned in Q2 FY25, Q3 FY25
Collaboration with Dr. Reddy's for biologics CDMO is expected to generate incremental revenue starting next financial year (FY26).
Mentioned in Q2 FY25, Q3 FY25
Cenexi is expected to achieve positive EBITDA by Q3 FY26, delayed from earlier Q4 FY25 guidance due to ANSM inspection impact.
Fast read
Guidance and risk preview
Management expects Cenexi to deliver positive EBITDA in Q3 FY26, with Q2 being lower due to summer shutdown.
Management acknowledged that Q2 FY26 will see lower EBITDA at Cenexi due to a one-month thermal shutdown, potentially delaying the turnaround traje...
View Risks →